GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2009

Sigma-Aldrich to Distribute Stemgent’s Gene Delivery Products for iPS Cells

  • Sigma-Aldrich entered into an exclusive, worldwide distribution agreement to offer Stemgent's portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (iPS) cells. The reprogramming technologies offered under the terms of the agreement involve viral vectors from Stemgent, lentivirus technology from Sigma-Aldrich, and dox Inducible expression from TET Systems.

    “Induced pluripotent stem cells have emerged as immensely useful tools for the modeling of human diseases, research and development of therapeutics, regenerative medicine, and the development of personalized cell-replacement therapies,” comments David Smoller, Ph.D., president of Sigma-Aldrich's research biotech business unit.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »